Robust physiologically based pharmacokinetic model of rifampicin for predicting drug–drug interactions via P‐glycoprotein induction and inhibition in the intestine, liver, and kidn...

por Asaumi, Ryuta, Nunoya, Ken‐ichi, Yamaura, Yoshiyuki, Taskar, Kunal S., Sugiyama, Yuichi
Publicado 2022

Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug

por Salem, Farzaneh, Nimavardi, Ali, Mudunuru, Jennypher, Tompson, Debra, Bloomer, Jackie, Turner, David B., Taskar, Kunal S.
Publicado 2023

Unmasking the Role of Uptake Transporters for Digoxin Uptake Across the Barriers of the Central Nervous System in Rat

por Taskar, Kunal S, Mariappan, T Thanga, Kurawattimath, Vishwanath, Singh Gautam, Shashyendra, Radhakrishna Mullapudi, TV, Sridhar, Srikanth K, Kallem, Raja Reddy, Marathe, Punit, Mandlekar, Sandhya
Publicado 2017

Physiologically‐based pharmacokinetic model‐based translation of OATP1B‐mediated drug–drug interactions from coproporphyrin I to probe drugs

por Mochizuki, Tatsuki, Aoki, Yasunori, Yoshikado, Takashi, Yoshida, Kenta, Lai, Yurong, Hirabayashi, Hideki, Yamaura, Yoshiyuki, Rockich, Kevin, Taskar, Kunal, Takashima, Tadayuki, Chu, Xiaoyan, Zamek‐Gliszczynski, Maciej J., Mao, Jialin, Maeda, Kazuya, Furihata, Kenichi, Sugiyama, Yuichi, Kusuhara, Hiroyuki
Publicado 2022

Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions

por Mochizuki, Tatsuki, Zamek‐Gliszczynski, Maciej J., Yoshida, Kenta, Mao, Jialin, Taskar, Kunal, Hirabayashi, Hideki, Chu, Xiaoyan, Lai, Yurong, Takashima, Tadayuki, Rockich, Kevin, Yamaura, Yoshiyuki, Fujiwara, Kaku, Mizuno, Tadahaya, Maeda, Kazuya, Furihata, Kenichi, Sugiyama, Yuichi, Kusuhara, Hiroyuki
Publicado 2022

Physiologically‐Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug–Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Reco...

por Taskar, Kunal S., Pilla Reddy, Venkatesh, Burt, Howard, Posada, Maria M., Varma, Manthena, Zheng, Ming, Ullah, Mohammed, Emami Riedmaier, Arian, Umehara, Ken‐ichi, Snoeys, Jan, Nakakariya, Masanori, Chu, Xiaoyan, Beneton, Maud, Chen, Yuan, Huth, Felix, Narayanan, Rangaraj, Mukherjee, Dwaipayan, Dixit, Vaishali, Sugiyama, Yuichi, Neuhoff, Sibylle
Publicado 2019

Industrial Perspective on the Benefits Realized From the FDA’s Model‐Informed Drug Development Paired Meeting Pilot Program

por Galluppi, Gerald R., Brar, Satjit, Caro, Luzelena, Chen, Yuan, Frey, Nicolas, Grimm, Hans Peter, Rudd, Deanne Jackson, Li, Chi‐Chung, Magee, Mindy, Mukherjee, Arnab, Nagao, Lee, Purohit, Vivek S., Roy, Amit, Salem, Ahmed Hamed, Sinha, Vikram, Suleiman, Ahmed A., Taskar, Kunal S., Upreti, Vijay V., Weber, Benjamin, Cook, Jack
Publicado 2021

Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective

por Kenna, J. Gerry, Taskar, Kunal S., Battista, Christina, Bourdet, David L., Brouwer, Kim L.R., Brouwer, Kenneth R., Dai, David, Funk, Christoph, Hafey, Michael J., Lai, Yurong, Maher, Jonathan, Pak, Y. Anne, Pedersen, Jenny M., Polli, Joseph W., Rodrigues, A. David, Watkins, Paul B., Yang, Kyunghee, Yucha, Robert W.
Publicado 2018